DE69934881D1 - Selective il-2 agonisten und antagonisten - Google Patents

Selective il-2 agonisten und antagonisten

Info

Publication number
DE69934881D1
DE69934881D1 DE69934881T DE69934881T DE69934881D1 DE 69934881 D1 DE69934881 D1 DE 69934881D1 DE 69934881 T DE69934881 T DE 69934881T DE 69934881 T DE69934881 T DE 69934881T DE 69934881 D1 DE69934881 D1 DE 69934881D1
Authority
DE
Germany
Prior art keywords
agonists
antagonists
selective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69934881T
Other languages
English (en)
Other versions
DE69934881T2 (de
Inventor
B Shanafelt
M Greve
Gary Jesmok
J Lembach
D Wetzel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aicuris GmbH and Co KG
Original Assignee
Aicuris GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris GmbH and Co KG filed Critical Aicuris GmbH and Co KG
Publication of DE69934881D1 publication Critical patent/DE69934881D1/de
Application granted granted Critical
Publication of DE69934881T2 publication Critical patent/DE69934881T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69934881T 1998-05-15 1999-05-13 Selective il-2 agonisten und antagonisten Expired - Lifetime DE69934881T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8008098A 1998-05-15 1998-05-15
US80080 1998-05-15
PCT/US1999/010643 WO1999060128A1 (en) 1998-05-15 1999-05-13 Il-2 selective agonists and antagonists

Publications (2)

Publication Number Publication Date
DE69934881D1 true DE69934881D1 (de) 2007-03-08
DE69934881T2 DE69934881T2 (de) 2007-11-08

Family

ID=22155135

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69934881T Expired - Lifetime DE69934881T2 (de) 1998-05-15 1999-05-13 Selective il-2 agonisten und antagonisten

Country Status (39)

Country Link
EP (1) EP1076704B1 (de)
JP (1) JP4276783B2 (de)
KR (1) KR100607609B1 (de)
CN (2) CN100366742C (de)
AR (1) AR020322A1 (de)
AT (1) ATE351907T1 (de)
AU (1) AU759697B2 (de)
BG (1) BG65139B1 (de)
BR (1) BRPI9910504B1 (de)
CA (1) CA2327349C (de)
CO (1) CO5070701A1 (de)
CU (2) CU23273B7 (de)
CY (1) CY1107533T1 (de)
CZ (1) CZ302071B6 (de)
DE (1) DE69934881T2 (de)
DK (1) DK1076704T3 (de)
DZ (1) DZ2788A1 (de)
ES (1) ES2281175T3 (de)
HK (1) HK1039963B (de)
HN (1) HN1999000075A (de)
HU (1) HU226142B1 (de)
IL (2) IL139136A0 (de)
MY (1) MY130274A (de)
NO (1) NO329235B1 (de)
NZ (1) NZ508098A (de)
PA (1) PA8472601A1 (de)
PE (1) PE20000475A1 (de)
PL (1) PL201675B1 (de)
PT (1) PT1076704E (de)
RO (1) RO122150B1 (de)
RU (1) RU2235729C2 (de)
SI (1) SI20643B (de)
SK (1) SK288100B6 (de)
SV (1) SV1999000061A (de)
TN (1) TNSN99090A1 (de)
TR (1) TR200003354T2 (de)
TW (1) TWI223663B (de)
UA (1) UA73719C2 (de)
WO (1) WO1999060128A1 (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058456A2 (en) 1999-03-30 2000-10-05 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinacious compounds
EP1935431A3 (de) 2000-05-15 2008-08-13 Health Research, Inc. Krebsbehandlungen unter Verwendung einer Kombination aus einem HER2-Antikörper und Interleukin-2
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
MY139948A (en) * 2000-09-28 2009-11-30 Bayer Corp Enhanced transfection system
US7723102B2 (en) * 2000-09-28 2010-05-25 Bayer Corporation Enhanced transfection system
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
CN100390282C (zh) * 2001-12-04 2008-05-28 默克专利有限公司 具有调节的选择性的il-2融合蛋白
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
DK1648931T3 (da) 2003-07-21 2011-03-07 Transgene Sa Multifunktionelle cytokiner
DE602004031341D1 (de) * 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
EP2149585B1 (de) 2003-11-04 2013-08-14 Novartis Vaccines and Diagnostics, Inc. Verwendung von antagonistischen anti-CD40-monoklonale Antikörper
WO2005085282A1 (en) * 2004-02-27 2005-09-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Il-15 binding site for il15-ralpha and specific il-15 mutants having agonists/antagonists activity
WO2005091956A2 (en) * 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
US8906356B2 (en) 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
CN101244261B (zh) * 2008-03-10 2010-09-15 山东大学 一种含未复性重组蛋白的生物制剂及其制备方法与应用
DE102008023820A1 (de) * 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
CA2749539C (en) 2009-01-21 2022-07-19 Amgen Inc. Compositions and methods comprising interleukin-2 mutants for treating inflammatory and autoimmune diseases
CN102101885B (zh) * 2010-09-01 2013-06-05 南京发士达生物科技有限公司 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途
CU23923B1 (es) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
WO2012065086A1 (en) 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
WO2012088446A1 (en) * 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
HUE029139T2 (hu) 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
WO2012119093A1 (en) * 2011-03-03 2012-09-07 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
EP3049445A4 (de) 2013-09-24 2017-10-25 Medicenna Therapeutics, Inc. Interleukin-2-fusionsproteine und verwendungen davon
LT3102595T (lt) 2014-02-06 2019-01-25 F. Hoffmann-La Roche Ag Interleukino-2 sulieti baltymai ir jų panaudojimas
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10150802B2 (en) 2014-04-24 2018-12-11 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
ES2807260T3 (es) * 2014-08-11 2021-02-22 Delinia Inc Variantes de IL-2 modificadas que activan selectivamente las células T reguladoras para el tratamiento de enfermedades autoinmunes
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CN109689694B (zh) * 2016-05-19 2022-11-22 通用医疗公司 与其受体IL-2Rβ结合的IL2作为用来增强自然杀伤细胞和调节性T细胞活性的平台
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
JP7261379B2 (ja) 2016-06-20 2023-04-20 カイマブ・リミテッド 抗ｐｄ－ｌ１抗体
CA3028829A1 (en) * 2016-06-22 2017-12-28 David Klatzmann Genetically modified t lymphocytes
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
EA201991142A1 (ru) 2016-11-08 2019-10-31 Варианты il-2 для лечения аутоиммунных заболеваний
BR112019011799B1 (pt) * 2016-12-13 2021-12-21 Delinia, Inc Proteína de fusão, proteína dimérica e composição farmacêutica
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
CN111107868A (zh) * 2017-05-24 2020-05-05 诺华股份有限公司 抗体细胞因子移植蛋白及使用方法
MX2019014023A (es) 2017-05-24 2020-02-17 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
CA3067909A1 (en) 2017-06-19 2018-12-27 Medicenna Therapeutics Inc. Uses and methods for il-2 superagonists, agonists, and fusions thereof
JP2020529976A (ja) * 2017-08-03 2020-10-15 シンソークス，インク． 自己免疫疾患の処置のためのサイトカイン抱合体
CN111615396A (zh) * 2017-11-21 2020-09-01 小利兰·斯坦福大学董事会 白介素-2的部分激动剂
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
CA3086199A1 (en) 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
WO2019158764A1 (en) 2018-02-16 2019-08-22 Iltoo Pharma Use of interleukin 2 for treating sjögren's syndrome
AU2019246389A1 (en) 2018-03-28 2020-08-27 Ascendis Pharma Oncology Division A/S IL-2 conjugates
TW202003551A (zh) 2018-03-28 2020-01-16 美商必治妥美雅史谷比公司 介白素-2/介白素-2受體阿法融合蛋白及其使用方法
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
CN112771072A (zh) * 2018-07-24 2021-05-07 生物技术Rna制药有限公司 Il2激动剂
US20210236599A1 (en) 2018-08-13 2021-08-05 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
PE20201418A1 (es) * 2018-09-17 2020-12-09 Gi Innovation Inc Proteina de fusion que comprende proteina il-2 y proteina cd80 y uso de la misma
CN113383013B (zh) 2018-12-21 2022-11-04 江苏恒瑞医药股份有限公司 一种人白细胞介素2变体或其衍生物
KR20220035333A (ko) 2019-05-20 2022-03-22 팬디온 오퍼레이션스, 인코포레이티드 Madcam 표적 면역관용
TW202115105A (zh) * 2019-06-24 2021-04-16 德商拜恩迪克Ｒｎａ製藥有限公司 Ｉｌ２激動劑
AU2020328038A1 (en) * 2019-08-13 2022-03-31 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
KR20220139293A (ko) 2019-12-12 2022-10-14 일투 파마 인터류킨 2 키메라 구축물
KR20220114595A (ko) 2019-12-17 2022-08-17 암젠 인크 치료에서의 사용을 위한 이중 인터류킨-2/tnf 수용체 효현제
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
US11491205B2 (en) 2020-01-14 2022-11-08 Synthekine, Inc. Biased IL2 muteins methods and compositions
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
EP4122952A4 (de) 2020-03-19 2024-05-29 Innovent Biologics Singapore Pte Ltd Interleukin-2-mutant und verwendung davon
WO2021201615A1 (ko) 2020-03-31 2021-10-07 한미약품 주식회사 신규한 면역 활성 인터루킨 2 아날로그
KR20230019889A (ko) 2020-06-03 2023-02-09 아센디스 파마 온콜로지 디비전 에이/에스 Il-2 서열 및 이의 용도
CN114507643A (zh) * 2020-10-29 2022-05-17 未来智人再生医学研究院(广州)有限公司 一种表达il-2的多能干细胞衍生物及应用
MX2023005030A (es) 2020-10-29 2023-05-16 Bristol Myers Squibb Co Proteinas de fusion para el tratamiento de enfermedades.
CN113308477A (zh) * 2021-04-08 2021-08-27 华南农业大学 一种鸭il-2基因真核表达重组质粒及其制备方法
AU2022350407A1 (en) 2021-09-22 2024-05-02 Fortvita Biologics (Singapore) Pte. Ltd. Interleukin-2 mutant and fusion protein thereof
CA3233644A1 (en) 2021-10-06 2023-04-13 David Klatzmann Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
WO2023245097A2 (en) * 2022-06-16 2023-12-21 Cephalon Llc Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof
WO2024056154A1 (en) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin-2 for use in treating autism spectrum disorder
FR3140287A1 (fr) 2022-10-03 2024-04-05 Arkema France Procede de granulation de composes azoiques et granules obtenus

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13

Also Published As

Publication number Publication date
SV1999000061A (es) 2000-03-14
NZ508098A (en) 2003-09-26
EP1076704B1 (de) 2007-01-17
NO329235B1 (no) 2010-09-20
CA2327349A1 (en) 1999-11-25
UA73719C2 (en) 2005-09-15
JP4276783B2 (ja) 2009-06-10
CA2327349C (en) 2010-10-26
PE20000475A1 (es) 2000-07-07
HK1039963B (zh) 2008-09-05
SK288100B6 (sk) 2013-07-02
KR100607609B1 (ko) 2006-08-02
NO20005762L (no) 2001-01-11
PT1076704E (pt) 2007-02-28
RO122150B1 (ro) 2009-01-30
CU23273B7 (es) 2008-04-09
HN1999000075A (es) 1999-09-29
TNSN99090A1 (fr) 2005-11-10
JP2002515247A (ja) 2002-05-28
CZ20004213A3 (en) 2001-05-16
TWI223663B (en) 2004-11-11
CY1107533T1 (el) 2013-03-13
SK17242000A3 (sk) 2001-07-10
TR200003354T2 (tr) 2001-03-21
CZ302071B6 (cs) 2010-09-29
CN100366742C (zh) 2008-02-06
HUP0101948A3 (en) 2003-08-28
HUP0101948A2 (hu) 2001-09-28
PL201675B1 (pl) 2009-04-30
ATE351907T1 (de) 2007-02-15
MY130274A (en) 2007-06-29
ES2281175T3 (es) 2007-09-16
BG104929A (en) 2001-09-28
DZ2788A1 (fr) 2003-12-01
CN101319247A (zh) 2008-12-10
AU4078499A (en) 1999-12-06
PA8472601A1 (es) 2000-09-29
WO1999060128A1 (en) 1999-11-25
SI20643B (sl) 2008-02-29
IL139136A (en) 2009-05-04
EP1076704A1 (de) 2001-02-21
IL139136A0 (en) 2001-11-25
CO5070701A1 (es) 2001-08-28
AU759697B2 (en) 2003-04-17
RU2235729C2 (ru) 2004-09-10
NO20005762D0 (no) 2000-11-14
PL344407A1 (en) 2001-11-05
CU23272A1 (es) 2008-04-09
BRPI9910504B1 (pt) 2016-08-09
CN101319247B (zh) 2012-12-12
KR20010043602A (ko) 2001-05-25
HU226142B1 (en) 2008-05-28
DE69934881T2 (de) 2007-11-08
DK1076704T3 (da) 2007-03-12
AR020322A1 (es) 2002-05-08
BR9910504A (pt) 2001-01-09
HK1039963A1 (en) 2002-05-17
SI20643A (sl) 2002-02-28
CN1309705A (zh) 2001-08-22
BG65139B1 (bg) 2007-03-30

Similar Documents

Publication Publication Date Title
ATE351907T1 (de) Selective il-2 agonisten und antagonisten
DE69913169D1 (de) Sportschuh und dafür vorgesehene dornen
DE69921723D1 (de) USB-Vorrichtung und USB- Knotenpunktvorrichtung
DE69932265D1 (de) Musikaktionsspielsystem und computerlesbare Aufzeichnungsvorrichtung
DE69911378D1 (de) Fluorierte ionomere und verwendung davon
DE69924002D1 (de) Kompressions-abgestimmtes bragggitter und kompressions-abgestimmter laser
DE69918107D1 (de) Ionomere und ionenleitende zusammensetzungen
DE60026169D1 (de) Selektive neurokinin-antagonisten
DE69835697D1 (de) Bauteile-bestückungsvorrichtung und bauteile-zufuhrvorrichtung
DE69925068D1 (de) Netzwerk und Knoteneinrichtung
DE60014137D1 (de) Schneidewerkzeug und werkzeughaltevorrichtung
DE60031119D1 (de) Richtbohrvorrichtung und -verfahren
DE69832657D1 (de) Empfangseinrichtungen und Empfangsverfahren
DE19983830T1 (de) Schneid-Vorrichtung
DE69903961T2 (de) Muscarinagonisten und antagonisten
DE69933476D1 (de) Fluorelastomer und vernetzbare zusammensetzung daraus
DE50015227D1 (de) Packung und Zuschnitt
ATE295839T1 (de) N-(3-ethinylphenylamino)-6,7-bis(2-methoxyethox )-4-chinazolinamin-mesylat-anhydrat und -monohydrat
DE69921110D1 (de) Bohrflüssigkeiten und zusatzstoffen
DE69805154T2 (de) Programmierbares Gerät
NO963331D0 (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
DE69911498D1 (de) Oszillator und Kommunikationsgerät
ATE231489T1 (de) N-sulphonyl und n-sulphinyl phenylglycinamide
DE29807261U1 (de) Schneidvorrichtung
DE50003007D1 (de) Schneidklemmkontakt und verbindungsklemme

Legal Events

Date Code Title Description
8364 No opposition during term of opposition